InfectoGnostics

Breaking New Ground in Diagnostics of Infections

The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections. More than 30 partners from science, medicine and industry are jointly developing novel solutions for fast and cost-effective on-site diagnostics of infectious diseases.

Read more our mission and the concept of our campus.

News

Find out more about current advancements in diagnostics and infection research in our most recent news or browse through our news archive.

Cross-Cluster Weeks Thuringia provide impulses for innovation

The Cross-Cluster Weeks Thuringia were again a complete success in 2021 with almost 800 participants. Topics like sustainable production, new materials, energy transition, resource efficiency, on-site analysis and therapy of infections or digitalization were discussed in a cross-sectoral exchange among the numerous interested parties in 14 events…

Read more
[Translate to English:]

Corona Genome Sequencing: Central German Company "nanozoo" Launches Portal for Free Data Analysis

The central German start-up company "nanozoo" – a member of the InfectoGnostics research campus in Jena – has launched a portal for the free analysis and processing of raw data from the genome sequencing of SARS-CoV-2 isolates. Within a few hours, the data of registered users will be processed and made available. The resulting genome sequences are…

Read more

Antibody Test for Coronavirus Developed with InfectoGnostics Partners in Jena and Weimar

An international team of researchers, including two InfectoGnostics partners - the Leibniz Institute for Photonic Technologies (Leibniz-IPHT) in Jena and the diagnostics company Senova in Weimar - has developed a rapid antibody test for the new coronavirus. Using a blood sample, it shows within ten minutes whether a person is acutely infected with…

Read more

InfectoGnostics Clinician Interviewed: Precision Medicine 2.0

The right treatment for the right patient at the right time - this approach of "precision medicine" is increasingly being used in the prevention of infections and sepsis. In an interview with the "Infectious Diseases Hub", Prof. Mathias Pletz, leading infectiologist at the University Hospital of Jena and member of the extended InfectoGnostics Board…

Read more

Events

Here you will find the current events in our network as well as an overview of previous events that have already taken place.

InfectoGnostics at 5th Munich Point-of-Care-Symposium

15.03.2022, 12.00 Uhr17.03.2022, 16.00 Uhr

Munich

Projects

  • ADA

    Adaptable decentralised diagnostics for veterinary and human medicine

    In the "ADA" project, a cost-effective, open test platform for screening for Staphylococcus aureus / MRSA in human and veterinary medicine is being developed.

    Erfahren hier Sie mehr über ADA .

  • TIPAT

    Training towards Innovative Personalized Antibiotic Therapy

    The research campus partners University Hospital Jena and the Paul Ehrlich Institute - supported by the InfectoGnostics office - participate in the EU-funded network Training towards Innovative Personalized Antibiotic Therapy (TIPAT). This Innovative Training Network (ITN) aims to train interdisciplinary specialists for the development of innovative personalized antibiotic treatment strategies. In particular, it aims to promote a better quantitative understanding of the interaction between drug, pathogen and host.

    Erfahren hier Sie mehr über TIPAT .

  • InfectoXplore

    Spektroskopische Plattform zur Diagnostik von Infektionen aus Blut

    Mit „InfectoXplore“ wird am InfectoGnostics Forschungscampus eine Diagnostik-Plattform aufgebaut, mit der erstmals auch aus Blutkulturen eine umfassende Raman-spektroskopische Erreger-Analyse durchgeführt werden kann.

    Erfahren hier Sie mehr über InfectoXplore .

  • Resistovac

    Testformate zur schnellen Erfassung des Impfstatus

    Im Projekt „RESISTOVAC“ werden verschiedene Testformate entwickelt, die zur schnellen Erfassung des Impfstatus von Menschen und Tieren eingesetzt werden können und so entscheidend zur Prävention von Infektionskrankheiten weltweit beitragen sollen.

    Erfahren hier Sie mehr über Resistovac .

  • POCT-ambulant

    Forschungs-Entwicklungs-Praxis-Dialog zur bedarfsgerechten Entwicklung von PoC-Tests

    Mit „POCT-ambulant“ entwickelt der Forschungscampus ein strukturiertes und systematisches Programm zur Beurteilung des Patientennutzens und des klinischen Bedarfes von Vor-Ort-Testverfahren (sogenannten Point-of-Care-Verfahren) im niedergelassenen Bereich.

    Erfahren hier Sie mehr über POCT-ambulant .

  • FastAlert

    Früherkennung von Erregern und Resistenzen in Abwasser

    In „FastAlert“ soll ein Analysesystem zur prozessnahen Erregerdetektion in Abwasseranlagen entstehen, um Infektionserreger und Resistenzgene zu überwachen.

    Erfahren hier Sie mehr über FastAlert .

Partners

Under the maxim "diagnostics before therapy", we successfully realise projects as a public-private partnerships (PPP) with strong partners from industry and science. On the page "partners" you will find an overview of all our campus members.  Here you can first get to know a random selection of our partners: